Nykode Therapeutics AS at Jefferies Healthcare Conference Transcript
Hello, everybody, good afternoon. I'd like to welcome you all again back to the 2022 Jefferies Healthcare Conference.
My name [Zed Zucker] and it is my pleasure today to be able to present to you, Michael Engsig and Agnete Fredriksen from Nykode. So I will pass it off to them.
Thank you very much. Once again, thanks for hosting us here at Jefferies. Pleased to be back.
Sure, you're all familiar with our forward-looking statements. So on that assumption, we'll move forward. I'm pleased to have with me here today, Agnete, our Co-Founder and Chief Innovation and Strategy Officer. I'm Michael Engsig, CEO of Nykode Therapeutics.
So for those of you who are not familiar with Nykode Therapeutics, Nykode is a clinical-stage immunotherapy company entirely focused on exploring and exploiting our proprietary immunotherapy platform, which uniquely targets the antigen presenting cells, which in turn results in a fast strong and long-lasting immune response.
We have a healthy mix
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |